Vertex's $4.9 Billion Gamble on a Kidney Drug Just Paid Off

Safety: The Part Pharma Usually Mumbles Through

A drug can hit every efficacy endpoint in the world, but if it makes patients miserable, it's dead on arrival. Povetacicept's safety profile, frankly, looked clean.

The most common side effects were mild-to-moderate respiratory infections and injection site reactions. No serious drug-related adverse events were reported. No deaths. And here's a telling detail: only 0.8% of patients on the drug dropped out of the trial, compared to 1.5% on placebo. When more people quit the sugar pill than the actual medicine, that's a good sign.

The $4.9 Billion Question: Was It Worth It?

When Vertex acquired Alpine Immune Sciences, some analysts side-eyed the price tag. Vertex was (and still is) a cystic fibrosis powerhouse, with margins in the mid-80s. But cystic fibrosis has a ceiling: roughly 97,500 eligible patients worldwide. You can only sell so many bottles of the same medicine before you've treated everyone who needs it.

So Vertex went shopping. It picked up a pain drug (Journavx, approved in January 2025 as a non-opioid alternative). It licensed gene-editing technology from CRISPR Therapeutics for type 1 diabetes. It launched Casgevy for blood disorders. And then it spent nearly $5 billion on a kidney drug.

The kidney bet looks like the biggest swing of the bunch. Analysts now project povetacicept could generate peak annual sales north of $4 billion. If those projections hold, Vertex would essentially recoup the acquisition cost every year at peak. In pharma M&A terms, that's like buying a house and having it pay for itself in rent within 12 months.

A Crowded Race With a Clear Frontrunner

Povetacicept isn't the only game in town for IgAN. Otsuka's Voyxact showed a 51.2% proteinuria reduction in its own trial, which looks comparable on the surface. But analysts at BMO flagged a critical wrinkle: Voyxact's results were notably weaker in North American patients, while povetacicept showed consistent efficacy across all geographic and ethnic subgroups.

That consistency matters enormously. When you're pitching your drug to the FDA (and to nephrologists prescribing it), you want data that holds up everywhere, not just in certain populations. BMO described povetacicept as a "clear competitor and potential leader" in the space.

Vera Therapeutics is also developing atacicept for IgAN, though povetacicept's numbers appear to outperform numerically. Stifel analyst Paul Matteis raised fair questions about long-term differentiation, but acknowledged the importance of the results.

What Happens Next

Vertex completed its rolling biologics license application (BLA) to the FDA by the end of March 2026. The company plans to use a priority review voucher, which essentially cuts the FDA's review clock from the standard 10-12 months down to about six. That puts a potential approval date around November 2026.

There's still one big piece of the puzzle missing, though. The RAINIER trial will deliver its final analysis at two years, measuring eGFR slope (a direct measure of how fast kidney function is declining). The 36-week proteinuria data is compelling enough for an accelerated approval, where the FDA greenlights a drug based on a surrogate marker while longer-term data rolls in. But the two-year kidney function readout will be what cements povetacicept's legacy.

The Bigger Picture

Vertex's kidney play is really a story about reinvention. The company built a $100 billion-plus market cap on the back of cystic fibrosis, a disease with a relatively small patient population. To keep growing, it needed to prove it could compete in larger, messier therapeutic areas.

With povetacicept's Phase 3 data in hand, Vertex just showed it can do exactly that. A $4.9 billion acquisition. A potentially best-in-class drug. A clean safety profile. And the financial firepower to fund whatever comes next.

The cystic fibrosis company isn't just a cystic fibrosis company anymore.